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Abstract: MGluR2 is G protein-coupled receptor that is targeted for diseases like anxiety, 
depression, Parkinson’s disease and schizophrenia. Herein, we report the three-dimensional 
quantitative structure–activity relationship (3D-QSAR) studies of a series of 1,3-dihydro-
benzo[b][1,4]diazepin-2-one  derivatives  as  mGluR2  antagonists.  Two  series  of  models 
using two different activities of the antagonists against rat mGluR2, which has been shown 
to be very similar to the human mGluR2, (activity I: inhibition of [
3H]-LY354740; activity 
II: mGluR2 (1S,3R)-ACPD inhibition of forskolin stimulated cAMP.) were derived from 
datasets composed of 137 and 69 molecules respectively.  For activity I study, the best 
predictive model obtained from CoMFA analysis yielded a Q
2 of 0.513, R
2
ncv of 0.868, 
R
2
pred = 0.876, while the CoMSIA model yielded a Q
2 of 0.450, R
2
ncv = 0.899, R
2
pred = 0.735. 
For activity II study, CoMFA model yielded statistics of Q
2 = 0.5, R
2
ncv = 0.715, R
2
pred = 0.723. 
These results prove the high predictability of the models. Furthermore, a combined analysis 
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between the CoMFA, CoMSIA contour maps shows that: (1) Bulky substituents in R7, R3 
and position A benefit activity I of the antagonists, but decrease it when projected in R8 and 
position B; (2) Hydrophilic groups at position A and B increase both antagonistic activity I 
and II; (3) Electrostatic field plays an essential rule in the variance of activity II. In search 
for  more  potent  mGluR2  antagonists,  two  pharmacophore  models  were  developed 
separately  for  the  two  activities.  The  first  model  reveals  six  pharmacophoric  features, 
namely  an  aromatic  center,  two  hydrophobic  centers,  an  H-donor  atom,  an  
H-acceptor atom and an H-donor site. The second model shares all features of the first one 
and has an additional acceptor site, a positive N and an aromatic center. These models can 
be used as guidance for the development of new mGluR2 antagonists of high activity and 
selectivity.  This  work  is  the  first  report  on  3D-QSAR  modeling  of  these  mGluR2 
antagonists. All the conclusions may lead to a better understanding of the mechanism of 
antagonism and be helpful in the design of new potent mGluR2 antagonists.  
Keywords: 3D-QSAR; mGluR2 antagonist; CoMFA; CoMSIA; pharmacophore modeling 
 
1. Introduction 
Glutamate  is  a  useful  excitatory  neurotransmitter of  the  nervous  system,  although  its  excessive 
amount in the brain can lead to cell death through a process called excitotoxicity, which consists of the 
over stimulation of glutamate receptors. Excitotoxicity occurs in neurological diseases such as Alzheimer’s 
disease, Parkinson’s disease and multiple sclerosis [1]. The major excitatory neurotransmitter substance 
in  the  mammalian  central  nervous  system  is  L-glutamate,  which  acts on  receptors that  are  highly 
heterogeneous and of two types: ionotropic glutamate receptors (iGluRs) that mediate fast-synaptic 
transmission in most neuronal synapses and metabotropic glutamate receptors (mGluRs) which are  
G-protein  Coupled  Receptors  linked  to  multiple  second  messengers  and  modulate the  ion  channel 
currents [2,3]. Until now, at least eight mGluRs have been described, subdivided into three groups 
based on their primary structure, second-messenger coupling, and pharmacology. Group I receptors 
include mGluR 1 and 5, group II mGluR2 and 3, and group III mGluR 4, 6, 7 and 8 [4]. These mGluRs 
play  essential  neuromodulatory  roles  throughout  the  brain,  as  such  they  are  attractive  targets  for 
therapeutic  intervention  for  a  number  of  psychiatric  and  neurological  disorders  including  anxiety, 
depression, Fragile X, Syndrome, Parkinson’s disease and schizophrenia [5].  
In  the  latest  decades,  pharmacological  agents  acting  at  specific  mGluR  subtypes  have  been 
developed.  In  particular,  mGluR2/3  agonists  showing  antipsychotic  properties  and  mGluR2/3 
antagonists  may  be useful as antidepressants and cognitive enhancers as demonstrated in different 
animal  models [6]. These agents include the group II -selective agonist LY354740 and antagonist 
LY341495 [7]. These agonists have been reported to have neuroprotective, anxiolytic/anti-panic and 
anti-Parkinsonism  properties,  as  well  as  anti-psychotic  potential  [8–10].  However, recently  studies 
showed that LY354740 has  been demonstrated to impair the spatial  navigation  memory using the 
water maze and produces a dose-dependent impairment of working memory in the delayed match to Int. J. Mol. Sci. 2011, 12                       
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position (DMTP) task in rats, although in humans there are no reports to date that mGluR2/3 agonists 
impair the cognitions [6,11]. 
Recently,  acting  as  mGluR2  and  3  non-competitive  antagonists,  a  series  of  in  vivo  active  and  
well  tolerated  1,3-dihydro-benzo[b][1,4]diazepin-2-one  derivatives  were  synthesized  by  
Woltering T.J. et al [12]. They were reported to partially inhibit the binding of the selective agonist 
[
3H]-LY354740 to rat mGluR2, fully block the effect of LY354740, (1S,3R)-ACPD and L-glutamate in 
cAMP  assays.  These  mGluR2/3  antagonists  show  pharmacological  potentiality  by  blockade  of the 
mGluR2/3 agonist LY354740-induced hypoactivity and  improvement of a working  memory deﬁcit 
induced either by LY354740 or scopolamine in the delayed match to position task (DMTP). Also, 
combination  studies  of  the  antagonists  with  a  cholinesterase  inhibitor  shows  apparent  synergistic 
effects on working  memory  impairment induced by scopolamine. In addition,  among the series  of 
mGluR2 antagonists reported, compound 8am was found to exhibit mild antidepressant-like activity in 
the mouse, indicating further potential use of mGluR2/3 antagonists as antidepressant drugs [12]. 
Moreover,  mGluR2  antagonists  have  been  considered  as  major  elements  of  a  pharmaceutical 
composition to treat and prevent acute or chronic neurological disorders including Alzheimer’s disease 
and  mild  cognitive  impairment  (United  States  Patent  7235547).  Also,  Addex  Pharmaceuticals  
(a pharmaceutical cooperation) has  made plans to move  mGluR2 antagonist into clinical trials  for 
Alzheimer’s  disease  [13]. The  great  potential  of  further  biological  and  pharmaceutical  function  of 
mGluR2 antagonist is still under exploration. Therefore, the antagonism of the series of 1,3-dihydro-
benzo[b][1,4]diazepin-2-one derivatives has great value to investigate. 
Quantitative  structure  activity  relationship  (QSAR)  has  been  widely  used  to  find  out  various 
interactive fields making impacts on activity, to predict the activities of the inhibitors and thus to help 
forecasting and designing of better specific ligands [14–16]. It is a mathematical model of correlation, 
statistically validated, between the variation on chemical structure and the activity proﬁle of a series  
of  compounds  [17].  Nowadays,  three-dimensional  (3D)  quantitative  structure  activity  relationship  
(3D-QSAR) techniques, especially comparative molecular ﬁeld analysis (CoMFA) and comparative 
molecular similarity analysis (CoMSIA) are routinely used in modern drug design [18]. Furthermore, 
pharmacophore  model  is  another  method  to  investigate  into  the  structure-activity  relationship  of 
molecules. Common pharmacophoric features can be obtained from pharmacophore model based on 
known active compounds, providing guidance for the rational design of novel selective chemicals. In 
addition,  molecular  docking,  which  is  also  attempted  in  this  paper,  is  utilized  more  and  more  in  
current  drug  design  process.  Here  we  focused  on  the  study  of  a  series  of  8-ethynyl-1,3-dihydro-
benzo[b][1,4]diazepin-2-one  derivatives  that  has  been  reported  as  new  potent  non-competitive 
mGluR2/3 antagonist [12]. The aim of the present study is to use the 137 newly fused compounds 
mentioned  above  as  a  data  set to  identify  their  requisite  structural  features  affecting  the  mGluR2 
antagonist effects by a combination of several in silico approaches including CoMFA, CoMSIA and 
pharmacophore modeling. Structure-activity relationship concerning mGluR3 is not investigated, for 
there are no reported experimental values of activity presently. As far as we know, this study provides 
the first 3D-QSAR study and pharmacophore modeling for the series of new mGluR2 antagonists. 
 
 
 Int. J. Mol. Sci. 2011, 12                       
 
 
6002
2. Results and Discussion  
To  judge  whether  a  QSAR  model  is  highly  qualified,  several  statistical  parameters  including 
especially the cross-validated correlation coefficient (Q
2), non cross-validated correlation coefficient 
(R
2
ncv), standard error of estimate (SEE) and F-statistic  values as well as the optimum  number  of 
components (OPN) should be evaluated. Various 3D-QSAR models were generated and the best model 
was selected based on the statistically signiﬁcant parameters obtained. For both 3D-QSAR studies, 
good correlations were observed in the obtained CoMFA and CoMSIA models demonstrated by the 
high values of Q
2, Rncv, Rpred and other statistical results. Table 1 summarizes the statistical results of 
the CoMFA and CoMSIA analyses.  
Table 1. Summary of comparative molecular ﬁeld analysis (CoMFA) and comparative 
molecular similarity analysis CoMSIA results for activity I/activity II. 
PLS Statistics  Activity I  Activity II 
  CoMFA  CoMSIA  CoMFA  CoMSIA 
Q
2  0.513  0.450  0.503  0.367 
R
2
ncv  0.868  0.899  0.715  0.657 
SEE  0.296  0.273  0.265  0.285 
F  96.022  101.353  20.907  24.927 
R
2
pre  0.876  0.735  0.723  0.667 
SEP  0.288  0.420  0.241  0.265 
OPN  7  8  6  4 
Contribution 
Steric  0.488  0.112     
Electrostatic  0.461  0.277  0.917  0.455 
Hydrophobic    0.184    0.409 
H-donor    0.135     
H-acceptor    0.256     
Clogp  0.051  0.035  0.083  0.136 
Q
2, cross-validated correlation coefficient after the leave-one-out procedure; R
2
ncv, non-cross-validated 
correlation coefficient; SEE, standard error of estimate; F, ratio of R
2
ncv explained to unexplained  
=  R
2
ncv/(1  −  R
2
ncv);  R
2
pre,  predicted  correlation  coefficient  for  the  test  set  of  compounds;  SEP, 
standard error of prediction; OPN, optimal number of principal components. 
2.1. Results for Activity I 
2.1.1. 3D-QSAR Statistical Results 
During the molecular modeling process, 110 compounds out of the total 137 mGluR2 antagonists 
were used as training set and the remaining 27 compounds were used as test set (shown in Tables S1–S4 
in supporting information). The best results were obtained at a column ﬁltering of 1 kcal/mol for both 
steric and electrostatic ﬁelds for CoMFA analysis. PLS analysis showed a Q
2 value of 0.513 with 7 
components  for  CoMFA,  indicating  a  good  internal  predictive  capacity  of  the  model.  A  high 
correlation coefficient of 0.868 for the non-cross-validated model shows its self-consistency. Int. J. Mol. Sci. 2011, 12                       
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In addition, other statistical results including a SEE of 0.296 and an F-test value of 96.022 are 
reported  (Table  1).  Steric  ﬁeld  descriptors  explain  0.488  of  the  variance,  while  the  electrostatic 
descriptors contribute 0.461, suggesting a balanced percentage of the influence exerted by the two 
fields  on  the  activity  of  the  antagonist.  In  addition,  ClogP  contributes  a  minor  percentage  of  5.1, 
indicating that the hydrophobicity of compound does affect its antagonistic activity to some extent. 
For  the  CoMSIA  analysis,  all  combinations  of  the  ﬁve  different  ﬁeld  descriptors  (the  steric, 
electrostatic, hydrophobic, H-bond-donor and H-bond acceptor) were used, with attempt to seek for the 
best CoMSIA model while avoiding the risk of possible omitting of some optimal ones. As a result, out 
of all CoMSIA models established using the same training set as used in the CoMFA analysis, the 
optimal CoMSIA model was made use of all ﬁve ﬁeld parameters, and reveals a validated Q
2 of 0.450 
for 8 components, a Rncv
2 of 0.899, F value of 101.353 and SEE of 0.273. The electrostatic ﬁeld was 
demonstrated contributing a lot to the model with a sum of 27.7 percentages. In addition, the hydrogen 
bond acceptor ﬁeld descriptor fulfills its role by correlating with the mGluR2 antagonist activity with a 
fraction  of  0.256.  Steric  field  contributes  11.2  percent  of  the  variances.  H-bond  donor  field  and 
acceptor field contribute 0.184 and 0.135 respectively. 
All the statistical parameters of CoMFA and CoMSIA obtained show that the models generated are 
reasonable. Furthermore, the accuracy of these models was elucidated using an external test set of 27 
compounds. With a high predictive coefficient R
2
pred of 0.876 (R
2
ncv = 0.868) for CoMFA and 0.735 
(R
2
ncv = 0.899) for CoMSIA achieved, the test sets potently validate the efficacy of the CoMFA and 
CoMSIA models. Figure 1A,B illustrate the correlation plots of the experimental versus the predicted 
pIC50 values of the training (ﬁlled black square) and test sets (ﬁlled blue circle) for the optimal CoMFA 
and CoMSIA models, respectively. Clearly, a good correlation was observed from this ﬁgure since the 
predicted values are almost as accurate as the experimental activities for the whole dataset, and all 
points are rather uniformly distributed around the regression line. This good agreement between the 
predicted and experimental activity data proves the satisfactory predictive ability of both the CoMFA 
and CoMSIA models. 
Figure 1. The ligand-based correlation plots of the predicted versus the actual pIC50 values 
using the training (filled black square) and the test (filled blue circle) set compounds based 
on (A) CoMFA for activity I (Dataset A: 137 compounds); (B) CoMSIA models for activity I 
(Dataset A: 137 compounds); (C) CoMFA for activity II (Dataset B: 69 compounds). 
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Figure 1. Cont. 
 
2.1.2. Contour Maps for Activity I 
Contour maps were generated as scalar products of coefficients and standard deviation, associated 
with each CoMFA or CoMSIA column. The maps generated depict regions having scaled coefficients 
80% (favored) or 20% (disfavored). To aid in visualization, the most active antagonist in the series 
(compound  8ao)  is  shown  superimposed  with  the  CoMFA  (Figure  2)  and  CoMSIA  contour  maps 
(Figure 3). The coefficient contour plots are essential to identify the important regions where some 
changes in the steric, electrostatic and hydrophobic ﬁelds may affect the biological activity. This is 
particularly  important  when  increasing  or  reducing  the  activity  of  a  compound  by  changing  its 
molecular  structural  features  contributing  to the  interaction  between  the  ligand  and  the  active  site 
region of a receptor. 
Figure  2.  CoMFA  StDev*Coeff  contour  maps  for  activity  I.  (A)  Steric  (green/yellow) 
contour map in combination with compound 8ao. Green contours indicate regions where 
bulky  groups  increase  activity;  yellow  contours  indicate  regions  where  bulky  groups 
decrease activity; (B) Electrostatic contour map (red/blue) in combination with compound 
8ao. Red contours indicate regions where negative charged groups increase activity; blue 
contours indicate regions where positive charged groups increase activity. 
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Figure  3.  CoMSIA  StDev*Coeff  contour  maps  for  activity  I,  with  8ao  as  reference 
molecule. (A) Steric (green/yellow) contour map. Green contours indicate regions where 
bulky  groups  increase  activity;  yellow  contours  indicate  regions  where  bulky  groups 
decrease  activity;  (B)  Electrostatic  contour  map.  Red  contours  indicate  regions  where 
negative charges increase activity; blue contours indicate regions where positive charges 
increase activity; (C) Hydrophobic contour map. Yellow contours indicate regions where 
hydrophobic  substituents  enhance  activity;  white  contours  indicate  regions  where 
hydrophilic  substituents  enhance  activity;  (D)  Contour  maps  illustrating  H-bond  donor 
features. The cyan contour represents the H-bond donor favored region, purple indicates 
the disfavored region; (E) CoMSIA contour maps illustrating H-bond acceptor features. 
The magenta contour indicates regions where H-bond acceptor groups increase activity, the 
red contour indicates the disfavored region for H-bond acceptor groups. 
 
2.1.2.1. CoMFA Contour Maps  
The contour maps of CoMFA denote the region in the space where the aligned molecules would 
favorably  or  unfavorably  interact  with  the  receptor.  Contribution  for  favorable  and  unfavorable 
interactions with the receptor in terms of steric (80% green, 20% yellow) and electrostatic (80% blue 
and 20% red) were shown. 
For steric contour map, the green contour mapped near R7 substituent suggests that a sterically 
bulky  group  is  favorable  and  increases  the  activity.  This  is  well  illustrated  by  the  example  that 
compound 8at (pIC50 = 8.40, R7 = −OEt) has higher activity than any other compounds with smaller 
substituents  at  the  position  R7,  including  especially  the  8as  (pIC50  =  8.00),  which  has  the  same Int. J. Mol. Sci. 2011, 12                       
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structure with 8at except for absence of groups in position R7. In addition, the large green region near 
the heterocyclic ring (ring D) and position A of the ring suggests that the activity I also benefits from 
bulky groups of these sites. This can be demonstrated by that fact that compounds of groups 7, 8 with a 
heterocyclic ring D at R3 position generally have higher activities than group 14 (with no ring at R3 
position). Also, in case where a heterocyclic ring D is commonly shared, 8am, 8an, 8ao (pIC50 = 8.70, 
position A = −CH3) respectively bear higher activities than 8i (pIC50 = 8.40), 8j (pIC50 = 8.10), 8m 
(pIC50 = 8.00) with no groups at position A. A yellow contour map shown towards the position R8 
indicates  that  the  longer  chain  substituents  towards  this  spatial  distribution  decrease  the  activity. 
Compounds 7g (pIC50 = 6.68) and 7r (pIC50 = 6.33) showing less antagonist activity are just due to 
their bulky propyl substituents that are projected in the yellow region. This is also the same with the 
yellow blocks appearing at position B of ring D. A drop in activity of compound 8ax (pIC50 = 8.22, 
position B = −CH3) when compared with 8at (pIC50 = 8.40, position B = −H) can illustrate this point. 
The CoMFA electrostatic contour plots for highly active compound 8ao are displayed in (Figure 2B). 
The  large  blue  polyhedron  partially  encompassing  the  pyridine  ring  D  indicates  a  favor  for 
electropositive  substituents  in  this  region.  Compounds  8ap  (pIC50  =  7.85),  8t  (pIC50  =  7.40),  8u  
(pIC50 = 6.56) are less potent than compounds 8am, 8an, 8ao (pIC50 = 8.70) just due to their strong 
negative groups (−OH and –NMe2) in these areas. Red polyhedron around the N atom at position 4 of 
ring D indicates that substituents should be electron deficient for high binding affinity with protein, 
which can be illustrated by the fact that 8h (pIC50 = 8.40, with N atom at position 4 of ring D) and 8ae 
(pIC50 = 8.30, with −OMe) enjoy higher activities than 8y (pIC50 = 7.59, with C atom at position 4) 
and 8aa (pIC50 = 7.89, with –Me) respectively. 
2.1.2.2. CoMSIA Contour Maps 
CoMSIA contribution maps denote those areas within the speciﬁed region where the presence of a 
group with a particular physico-chemical property will be favored or disfavored for good biological 
activity.  With  8ao  as  reference  in  the  background,  CoMSIA  steric  (Figure  3A)  and  electrostatic 
contour maps (Figure 3B) show favorable and unfavorable regions that are highly similar to maps 
derived from the CoMFA analysis above, thus are not discussed here.  
Figure  3C  shows  the  CoMSIA  hydrophobic  ﬁeld  contour  map,  where  the  yellow  (hydrophobic 
favorable) and white (hydrophobic unfavorable) contours represent 80% and 20% level contributions 
respectively. Yellow region at positions R8 and R7 indicates hydrophobic substituents like −CF3, −Ph 
and -C≡C- resulting in a higher activity of mGluR2 antagonist. This can be illustrated by the sudden 
drop in activity of chemical 14w (pIC50 = 4.59, with a hydrophilic group −OH involved) comparing 
with 14u, 14v, 14x (pIC50 all above 6.00).  
Figures 3D and 3E depict the H-bond donor and acceptor contour maps of the CoMSIA models. 
Cyan color indicates the regions where H-bond donor acts as favored and purple color refers to the 
disfavored regions, respectively. Magenta contours encompass regions where H-bond acceptor will 
lead  to  improved  biological  activity,  which  may  result  in  the  fact  that  molecules  with  N  atom  
at position 4 of ring D such as 8av (pIC50 = 8.40), 8au (pIC50 = 8.10), 8am (pIC50 = 8.70), 8ao  
(pIC50 = 8.70) generally  have  larger pIC50 value than 7z and 8aa~8ag  molecules (pIC50 generally 
around 7.9–8.0) with position C atom at position 4. Red contours indicate an H-bond acceptor located Int. J. Mol. Sci. 2011, 12                       
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near the red regions will result in impaired biological activity. Compound 8l (pIC50 = 7.18, position  
B = −CF3) bearing lower activity than 8m (pIC50 = 8.00, position B = c-propyl), 8n (pIC50 = 8.40, 
position  B  =  i-propyl)  can  be  exemplified  to  demonstrate  the  disfavor  for  H-bond  acceptor.  The 
contour  maps  for  H-bond  donor  and  acceptor  fields  may  guide  the  exploration  of  the  H-bond 
interaction between the antagonists and the protein.  
2.2. Results for Activity II 
2.2.1. 3D-QSAR Statistical Results 
The dataset B composed of 69 compounds with reported experimental activities for (1S,3R)-ACPD 
inhibition of forskolin stimulated cAMP were divided into a training set consisting of 57 compounds 
and a test set containing 12 chemicals to derive the 3D-QSAR models (supporting Tables S1–S4).  
For CoMFA analysis, different from activity I studies, the optimal model consists only electrostatic 
ﬁeld descriptors with while ClogP still included in, and reveals a statistical result of Q
2 = 0.503 with 6 
components, R
2
ncv = 0.715, SEE = 0.265, F = 20.907. CoMFA electrostatic field accounts for 0.917 of 
the variance. In addition, ClogP contributes 8.3 percentages, suggesting the antagonistic activity of the 
mGluR2 antagonist is influenced by its hydrophobicity moderately. All five fields were employed to 
obtain the best CoMSIA model. The optimal model consisting of electrostatic and hydrophobic fields 
was generated. However, the result isn’t ideal statistically (Table 1). Therefore, the CoMFA model is 
mainly analyzed here.  
For  the  optimal  CoMFA  model,  the  external  test  sets  produced  an  R
2
pred  of  0.723,  which  is 
approximate to R
2
ncv (0.715) for the training sets. This potently validates the predictive ability of the 
CoMFA  model  established.  Figure  1C  depicts  the  correlations  between  the  experimental  and  the 
predict activities for both the training and test sets for the CoMFA model. A good agreement between 
the predicted activities and experimental data was observed from the plot. 
2.2.2. Contour Maps for Activity II 
The optimal CoMFA model is selected to construct the “stdev*coeff” contour maps to view the ﬁeld 
effects on the target features. 
The maps generated depict regions having scaled coefficients 80% (favored) or 20% (disfavored). 
To aid in visualization, compound 8av as the most active mGluR2 antagonist in the series, is shown 
superimposed with the CoMFA contour map (Figure 4). 
Figure 4 shows the electrostatic contour maps obtained from the CoMFA analysis. The large red 
polyhedrons  around  the  O  and  N  atoms  of  ring  II  indicate  the  favor  of  electronegative  charged 
substituents for the synthesis of potent antagonists. Similar to the electrostatic contour maps obtained 
from activity I, a large blue contour partially encompasses the ring D, which indicates a disfavor for 
electronegative substituents in this region, is observed. Compared with 8am, 8an, 8ao (pIC50 all above 
8.30),  compound  8ap  (pIC50  =  7.82)  suffers  a  sudden  drop  of  potency,  due  to  their  strong 
electronegative atom O. The small red isopleths above the N atom in position 4 of the ring suggest that 
substituents should be electron rich for high binding affinity with protein. This explains the high pIC50 Int. J. Mol. Sci. 2011, 12                       
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value of 8am~8ax (with N atom at position 4 of ring D), comparing with 7z and 8aa~8ag (with C atom 
at position 4). 
Figure 4. CoMFA electrostatic contour map for activity II, in combination with compound 
8av. Red contours indicate regions where negative charged groups increase activity; blue 
contours indicate regions where positive charged groups increase activity. 
 
2.3. Homology Modeling Results and Docking Study  
In order to ﬁnd the optimal orientation of the ligand in the binding pocket of the protein, docking 
studies were also attempted. However, a complete validated crystal structure for mGluR2 has  not yet 
been established. Thus, a homology model must be built based on the amino acid sequence, with a 
proper protein with similar structure and sequence as template. Based on chain B of template 2e4u 
(obtained from protein data bank), a comparative model of mGluR2 with a high sequence identity of 
65.4% covering regions 23 to 558 of a total of 872 amino acids (data shown in Figure S3 contained by 
support  information)  was  successfully  created. The  model  established  contains  an  orthosteric  site, 
which is the active site of the protein. But according to the study of Woltering T.J., the orthosteric site 
is not the binding site of the series of antagonist we investigated [12]. Instead, an allosteric site which 
locates in the 7 transmembrane (7TM) domain of mGluR2, maybe the binding site of the antagonist 
due to its non-competitive nature. The series of antagonists have been reported a high affinity for 
allosteric site [12]. Furthermore, instead of a common allosteric site, multiple allosteric sites covering a 
larger binding region is suggested for mGluR2 negative allosteric modulators such as the antagonists 
we focus on. Their binding region is defined as the inward-facing top half of the 7TM helices [5]. 
Unfortunately, according to the latest sequence reported by H.Y Zhou, the 7TM region happened to be 
in region 554 to 872, which is not contained in modeled residue range [19].  
Using bovine Rhodopsin crystal structures 1F88 and 1GZM, which is also a transmembrane protein, 
to build TM structure of GPCRs (G protein-coupled receptor) like mGluR1 and mGluR5, is applied 
recently [20–22]. Thus we attempted to build mGluR2 homology model based on 1F88 and 1GZM. In 
the present work, several homology models are built using this potentially effective template by a 
variety  of  modeling  tools  including  the  Swiss  Model,  Modweb,  M4T,  ESyPred3D  and  Modeller,  
but  only  receiving  identities  below  20%  (data  not  shown),  which  made  the  model  statistically 
insufficiently to be a valid mGluR2 structure. This may result from the low sequence identity (less than 
20%) shared by different classes of GPCR, despite of their common conﬁrmation of a hepta-helical 
architecture in the mGluR transmembrane [5]. The homology model reveals low sequences identity Int. J. Mol. Sci. 2011, 12                       
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and the unideal docking results. Thus to further investigate into the structure-activity relation of the 
series of antagonists, pharmacophore models were established based on the two activities. 
2.4. Pharmacophore Modeling 
Presently, models for mGluR2 antagonists is not developed yet, though pharmacophore models of 
mGluR2 agonists have been established [23]. Herein, prior to quantitative pharmacophore development, 
a  common-feature  pharmacophore  modeling  study  was  conducted  in  order to  identify  the  features 
required for effective mGluR2 antagonists.  
DiscoTECH  was  employed  to  generate  a  collection  of  pharmacophore  queries  from  a  series  of 
compounds some or all of which are active against a particular biological target such that all or most of 
active  compounds  satisfy  the  queries.  Presently,  50  highly  active  compounds  participated  in  the 
establishment of pharmacophore model for the two activities separately. The most active compounds 
for  activity  I  (8ao)  and  for  activity  II  (8av)  were  selected  as  reference  molecules  for  the  two 
pharmacophore  models  respectively.  The  maximum  number  of  conformers  generated  for  each 
compound was 50, and seven conformers were then selected.  
2.4.1. Pharmacophore Model for Activity I 
In total, nine models (as shown in Table 2) were generated using the most active 50 antagonists 
with no omitting for activity I studies. Model_001 (Figure 5A) was selected for subsequent studies 
despite its second highest score value (1.8562) because it has useful features of a higher diversity 
compared with model_002 (Figure 5B), which possesses the highest score (2.3577). 
Table 2. Number of models obtained along with the pharmacophoric features and tolerance 
values for each of the DISCO pharmacophoric run for activity I. 
MODEL  SIZE 
a  HITS 
b  SCORE 
c  TOLERANCE 
d  DMEAN 
e 
MODEL_002  6  50  2.3577  0.25  3.4348 
MODEL_001  6  50  1.8562  0.25  3.4163 
MODEL_005  7  50  1.7220  0.25  3.0344 
MODEL_009  7  50  1.3646  0.25  3.4012 
MODEL_003  7  50  1.3629  0.25  3.3955 
MODEL_006  7  50  1.3607  0.25  3.3880 
MODEL_008  6  50  0.6783  0.25  2.0754 
MODEL_004  6  50  0.3735  0.25  2.8621 
MODEL_007  6  50  0.3733  0.25  2.8616 
a SIZE, number of features in the model; 
b HITS, number of molecules that matched during 
the research; 
c SCORE, an overall measure of fit and of overlap for the entire collection of 
structure; 
d TOLERANCE, initial tolerance setting (from 0.25 to 2.5); 
e DMEAN, average 
inter-point distance. 
Figure 5A shows the optimal pharmacophore model (model_001) obtained with a score of 1.8562 
and  tolerance  distance  of  0.25  Å.  The  model  has  six  essential  features  required  for  high  receptor 
binding affinity, which contain two hydrophobic sites (HP1 and HP2), an H-bond donor atom (HD), an Int. J. Mol. Sci. 2011, 12                       
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H-bond donor site (DS), one H-bond acceptor atom (HA) and an aromatic center (AR). The distances 
between these pharmacophoric features are listed in Table 3. Two aromatic ring (ring I and ring III), a 
heterocyclic ring (ring II) containing N and a constrained conformation features are common in all the 
50 chemicals. The hydrophobic center and the planar group serve as the rigid portion of the molecular 
scaffold that satisﬁes the overall geometric and steric requirements of binding. 
Figure 5. The pharmacophoric features derived of (A) model_001 for activity I with six 
features generated; and (B) model_002 for activity I with six features generated presented 
in  template  molecule  8ao,  respectively.  AR  represents  aromatic  center;  HP  refers  to 
hydrophobic center; HD and HA are short for H-bond donor and acceptor respectively; DS 
refers to H-bond donor site. The distances (Ǻ) between these sites are marked in white lines.  
 
Table  3.  Relative  intramolecular  distances  between  pharmacophoric  feature  points  for 
model_001 of activity I (Ǻ). 
  AR1  HP1  DS  HP2 
HA  2.83  2.83  3.00  3.63 
HD  2.83  2.83  3.00  3.63 
DS  4.91  4.91    4.02 
HP2  6.43  6.43  4.02   
AR represents aromatic center; HP refers to hydrophobic center; HD and HA are short for H- bond 
donor and acceptor respectively; DS refers to H-bond donor site. 
This model has the characteristic features required for an ideal pharmacophoric query, because it 
possesses the important interactions required for this series of antagonists and was consistent with 
previously reported scaffold of potent antagonists [12]. Closer inspection of the pharmacophore model 
reveals that H-bond donor and H-bond acceptor atoms were in agreement with the results from the 
CoMSIA model. To be considered as a hit, a compound has to ﬁt all the features of the pharmacophore 
model consequently. Int. J. Mol. Sci. 2011, 12                       
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2.4.2. Pharmacophore Model for Activity II 
For activity II studies, based on 50 compounds of high antagonistic activity, only one model was 
obtained with a score of 1.8286 (as shown in Table 4) and tolerance of 0.25 Å. Nine essential features 
are observed in this model required for the high antagonistic activity, including two hydrophobic sites 
(HP1 and HP2), an H-bond donor atoms (HD), one H-bond donor site (DS), one H-bond acceptor site 
(AS), one H-bond acceptor atom (HA), one positive N (PN) and two aromatic centers (AR1 and AR2). 
Figure 6 shows the pharmacophoric features generated in this model, with the most active compound 8av 
for activity II as reference. The distances between these pharmacophoric features are listed in Table 5. 
Table 4. Number of models obtained along with the pharmacophoric features and tolerance 
values for each of the DISCO pharmacophoric run for activity II.  
MODEL  SIZE 
a  HITS 
b  SCORE 
c  TOLERANCE 
d  DMEAN 
e 
MODEL_001  9  50  1.8286  0.25  3.3280 
a SIZE, number of features in the model; 
b HITS, number of molecules that matched during 
the research; 
c SCORE, an overall measure of fit and of overlap for the entire collection of 
structure; 
d TOLERANCE, initial tolerance setting (from 0.25 to 2.5); 
e DMEAN, average 
inter-point distance. 
Figure  6. The pharmacophoric  features derived  of  model_001  for activity II with  nine 
features generated presented in template molecule 8av. AR represents aromatic center; HP 
refers  to  hydrophobic  center;  HD  and  HA  are  short  for  H-bond  donor  and  acceptor 
respectively; PN refers to positive N; DS and AS represent H-bond donor site and acceptor 
site respectively. The distances (Ǻ) between these sites are marked in white lines. 
 
Table  5.  Relative  intramolecular  distances  between  pharmacophoric  feature  points  for 
model_001 of activity II (Ǻ). 
  AR1  HP1  DS  HP2 
HA  2.83  2.83  3.00  3.63 
HD  2.83  2.83  3.00  3.63 
DS  4.91  4.91    4.02 
HP2  6.43  6.43  4.02   
AR represents aromatic center; HP refers to hydrophobic center; HD and HA are short for H-bond 
donor and acceptor respectively; PN refers to positive N, DS and AS represent H-bond donor site 
and acceptor site respectively. Int. J. Mol. Sci. 2011, 12                       
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An additional positive N, an acceptor site and an aromatic center are generated besides those similar 
features shared with the pharmacophore model generated previously for activity I, indicating a necessity 
of the presence of positive N and acceptor atom for the synthesis of potent mGluR2 antagonists that 
perform well in cAMP test. Compounds contain all the nine features of the pharmacophore model are 
supposed to be more capable of performing antagonistic activity towards mGluR2. 
For  both  activity  I  and  II  studies,  pharmacophore  features  derived  are  in  range  of  the  tricycle 
scaffold. This indicates that the basic scaffold features participate significantly in the pharmacologic  
effect of the antagonist.  Using the  models developed, a new effective  scaffold that contains these 
phamacophore features can be synthesized. In addition, CoMFA and CoMSIA contour maps derived 
denote  the  favorable  features  of  substituents.  With  a  combination  of  phamacophore  features  and 
CoMFA, CoMSIA contour maps, new potent antagonists can be designed. 
2.5. Comparison between the Two Activities 
Out of the 137 compounds employed in the investigation, 69 have both antagonistic activity I and II. 
To explore the possible relationship of the two potencies, a mathematical model is established and its 
corresponding plot using activity I and II as the X and Y coordinate respectively is drawn (Figure 7) 
based on these molecules. Clearly, a good linear correlationship is observed between the two activities 
with a correlation coefficient of R2 = 0.39. This may suggests that the activities of these antagonist in 
radioligand binding studies (Rat mGluR2 [
3H]-LY354740 binding, activity I) and in functional Cyclase 
Inhibition Assay (cAMP assay, activity II), though differ considerably, correlate with each other to a 
significant extent. The prediction that the binding ratio reflected the functional efficacy of a compound 
was also supported by  measurement of the ability of a number of compounds acting at dopamine 
receptors to inhibit rD2(444)-mediated inhibition of cyclic AMP production [24]. However, the pIC50 
value of the two activities  still differs  from each other, due to the different  mechanism of cAMP 
production and binding assay: Radioligand binding studies and cAMP assay are two strategies in drug 
screening  technology  to  investigate  the  activity  of  a  ligand.  cAMP  assay  is  based  on  a  second 
messenger and assesses the antagonistic activity of a ligand through the level of cAMP. That enables 
us to appreciate the molecular features of inhibition by the regulatory subunits as well as the activation 
by cAMP [25]. Radioligand binding studies do not involve the signal path, but directly investigate into 
the interaction between the radiolabelled ligands and the receptor. The first objective in binding assay 
is to ensure that the binding equilibrium is reached. Then KD, a parameter to describe the affinity of a 
ligand for a receptor can be calculated [26].  
In general, CoMFA and CoMSIA statistic results for the two activities differ in several aspects.  
(I) The best models for activity I employ all field descriptors in both CoMFA and CoMSIA (steric and 
electrostatic  in  CoMFA  and  steric,  electrostatic,  hydrophobic,  H-donor,  H-acceptor  in  CoMSIA) 
analyses. While for activity II, optimal model contains only electrostatic field in CoMFA analysis; (II) 
Steric  field  exerts  deeper  influence  on  activity  I  rather  than  activity  II,  for  in  activity  I  study,  it 
contributes  considerable  percentages  in  both  CoMFA  (48.8%)  and  CoMSIA  (11.2%)  analysis. 
However, for activity II study, neither the best CoMFA model nor the best CoMSIA model employs 
steric  field  as  a  contributor to the  variance  of  the  activity;  (III)  Electrostatic  field  clearly  plays  a 
dominant role in the variance of activity II, while for activity I, more factors including steric field, Int. J. Mol. Sci. 2011, 12                       
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hydrophobic field, H-donor and H-acceptor field contribute to the variance of activity of the series of 
antagonists; (IV) The hydrophobicity of a antagonist exerts more influence on its activity II rather than 
activity I  for two reasons.  Firstly, hydrophobic  field plays  more essential role  in the  later one on 
improving  the  value  of  statistical  parameters  (Q
2,  R
2
ncv,  R
2
pre)  that  are  crucial  for  evaluating  the 
reliability of the model. Thus, in the best CoMSIA models, hydrophobic field contributes a higher 
percentage to activity II (40.9%). Furthermore, ClogP, which  is a well  established  measure of the 
compound’s hydrophobicity. Thus, it contributes more in cAMP functional assay (activity II), with 
8.3% (activity II) over 5.1% (activity I) in CoMFA and 13.6% (activity II) over 3.5% (activity I) in 
CoMSIA. These differences in statistic result may result from the difference in mechanism of the two 
experiments revealing the activity of the antagonist. 
Figure 7. A correlation plot of activities for activity I (affinity test: partial displacement of 
[
3H]-LY354740) and activity II (cell  based test:  inhibition of effect of1S,3R-ACPD on 
cAMP level). 
 
From  the  differences  above,  we  may  conclude  that  factors  like  the  steric  feature,  electrostatic 
feature, hydrophobicity of a function group all need to be considered to best improve the performance 
of  the  antagonists  in  radioligand  binding  assay.  However,  simply  confusing  on  the  electrostatic 
character as well as the hydrophobicity of the substituents  may  help design drugs showing potent 
antagonism in cAMP assay. 
Analysis of the 3D-QSAR contour maps derived from activity I and activity II suggest that they 
generally have very similar structural requirements for potent ligands. The electrostatic contour maps 
all indicate that electropositive groups above N atom at position 4 of ring D will benefit the potency of 
the antagonist. Moreover, a large blue contour partially encompassing the pyridine ring is observed in 
all four of the contour maps. Still, a subtle difference exists: electropositive groups above the O atom 
of ring II decrease the activity I while favor the activity II. Also, large red contour around the N atom 
of ring II suggests a favor for electropositive substituents or atoms. These differences and similarities 
in molecular structural features of potent antagonists may help increasing or reducing the activity of 
the compound by changing its substituents. 
In addition, the pharmacophore models derived from the two activities generally share the same 
features, excepting for a few difference. An H-donor atom, an H-donor acceptor atom, an H-donor site, Int. J. Mol. Sci. 2011, 12                       
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two hydrophobic centers and an aromatic ring are common features for the two models. Besides, for 
pharmacophore model of activity II, a positive N, an H-bond acceptor site and an additional aromatic 
ring are featured as essential characters of potent drugs. Thus, here the active sites shared by the two 
models  are  considered  fundamental  pharmacophore  features  for  potent  mGluR2  antagonists.  The 
highly similarity of the two models may reflect the predict ability of radioligand binding assay towards 
pharmacophore function of the antagonists. These models can be used as guidance for the design of 
new mGluR2 antagonists of high activity and selectivity.  
3. Material and Methods 
3.1. Dataset and Biological Activity 
A  total  of  137  8-ethynyl-1,3-dihydro-benzo[b][1,4]diazepin-2-one  derivatives  with  common 
characteristics  of  inhibiting  the  [
3H]-LY354740 binding  to  rat  mGluR2  receptors  were  adopted as 
dataset  A  to  build  models  for  activity  I  studies.  Compound  4,  which  has  identical  structure  but 
different  activity  statistics  than  7p,  was  discarded  from  the  dataset  as  suspected  error  statistic.  In 
addition, compound 3 and 15o are identical both in structure and statistics, and 15o is adopted. Also, 
for activity II, 69 among the 137 compounds with a statistically reported function of inhibiting the 
forskolin stimulated cAMP production were adopted as dataset B to build models. The statistics were 
collected from the experimental values of Woltering T.J. et al. [12]. The original names of compounds 
in the four articles are preserved. The in vitro biological activities of these compounds were converted 
into  the  corresponding  pIC50  (−log  IC50)  values,  which  were  used  as  dependent  variables  in  the  
3D-QSAR analyses. PIC50 values and structures of 25 typical  molecules are shown in Table 6. In 
approximately a ratio of 4:1, the whole data set was divided into training (110 molecules) and test  
(27 molecules) sets in models based on activity I and training (57 molecules) and test (12 molecules) 
sets in models for activity II, respectively. With a desired function of representing the entire dataset to 
the most, the test set chemicals were picked considering several criterions: First and foremost, their 
pIC50 values are randomly  but uniformly distributed in the range of the  values  for the whole  set. 
Furthermore, the collection of their structures is typical enough to represent the entire dataset. The 
training and test set are listed in Tables S1–S4 (supporting information). All molecular modeling and 
3D-QSAR studies were performed using the SYBYL6.9 molecular modeling software package (Tripos 
Associates, St. Louis, MO,  USA). Partial atomic charges were calculated by the Gasteiger-Huckel 
method [27], energy minimization and conformational search were performed using Tripos molecular 
mechanics force ﬁeld [28] by conjugating method with a convergence criterion of 0.001 kcal/mol. To 
obtain relatively stable conformation, the energy gradient limit was set at 0.05 kcal/mol Å. Table S1–S4 
(Supporting Information) lists all the structures and biological values (pIC50) of the dataset, and the 
representative skeletons and pIC50 values are depicted in Table 6. Int. J. Mol. Sci. 2011, 12                       
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Table 6. Representative structures and inhibitory activities (pIC50) of the dataset. 
N
H
N O R8
R7
R3
 
NO.  R3  R8  R7  Activity I   Activity II 
1  H  Me  H  5.1938   
2  CN  Ph-C≡C-  H  7.4685  7.7696  
14u  CN  2-Thiazolyl-C≡C-  H  6.5229   
14v  CN  2-Pyridyl-C≡C-  H  6.0605   
14x  CN  H2C=C(Me)-C≡C-  H  6.3979   
14aa  CN  Ph-C≡C- 
N
NMe 
6.5560   
15c 
N
N
 
2-F-C6H4-C≡C-  H  7.6990  7.7959  
15m 
N
N
 
Ph-C≡C-  -OCH2CN  7.7447  7.8861  
15q 
N
N
N
 
4-F-C6H4-C≡C-  -OH  7.6990  7.7696  
7g 
N
N
 
Cyclo-propyl  H  6.6778   
7o 
N
N
N
 
4-F-C6H4-  H  7.5086  7.4437  
7z 
N
N
N
 
F3C-  Iso-butylN(Me)  7.9586  7.8539  
7ac 
N
N
N
 
F3C-  MeO  7.5376  7.1308  
8a 
N
N
 
F3C-  Me  7.9208  7.7212  
8h 
N
H
 
F3C-  Me  8.3979  7.9586  
8y 
N  
F3C-  Me  7.5850  7.5229  
8aa  N
Me
 
F3C-  Me  7.8861  8.3010  
8ae  N
OMe
 
F3C-  Me  8.3010  8.0000  Int. J. Mol. Sci. 2011, 12                       
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Table 6. Cont. 
NO.  R3  R8  R7  Activity I   Activity II 
8aj 
N
N
 
F3C-  Me  8.2218  7.3010  
8ao 
N
Me
 
F3C-  Me  8.6990  8.3979 
8av 
N
Me
 
Cl  Cl  8.3979  8.6990 
3.2. Conformational Sampling and Alignment 
Molecular alignment of compounds, which align all the compounds together by common scaffold, 
is a key step in the process of establishing 3D-QSAR models [29]. In the alignment, a molecule with 
relatively high biological activity and fairly fixed conformation is usually adopted as template. In this 
work, the most active compounds for the two activities: 8ao (activity I, pIC50 = 8.7) and 8av (activity II, 
pIC50 = 8.7) were used as template molecules in the two models respectively. The tricycle which they 
share with other molecules was chosen as the common scaffold. Figure 8A describes the common 
substructure for the alignment which is marked in red. A ring in position R3 was named ring D and 
positions A, B and 4 are shown in the figure. Based on an atom-by-atom superimposition principle, the 
ligand-based  alignment of the  molecules  was carried out by using  substructure-alignment  function 
available in SYBYL. Figure 8B and Figure 8C show the resulting ligand-based alignment model of 
activity I and activity II respectively. 
Figure 8. Scaffold of the mGluR 2 antagonists and molecular alignment of compounds for 
two  models.  (A)  Common  substructure  of  the  molecules  is  shown  in  red  with  8ao  as 
template molecule, and the heterocyclic ring (not commonly shared) as a substituent in 
position R3 is named ring D to better describe some compounds in group 8; (B) For activity 
I, molecular alignment using 137 molecules of dataset A; (C) For activity II, alignment 
model using 69 compounds of dataset B. 
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Figure 8. Cont. 
 
3.3. CoMFA and CoMSIA Field Calculation 
CoMFA approach, proposed by Cramer and co-workers in 1988, describes the molecular properties 
by 3D steric (Lennard–Jones) and electrostatic (Coulomb) fields, evaluated over a lattice of points. In a 
similar approach described as the (CoMSIA) by Klebe and co-workers in 1994, a probe atom is used to 
calculate the similarity indices, at regularly spaced grid points, for the pre-aligned molecules.  
In CoMFA calculations, the aligned training set molecules were placed in a 3D grid box. The steric 
and electrostatic ﬁeld energies were calculated using sp
3 carbon as probe atom. The energies were 
truncated to  30  kcal/mol.  CoMFA  method  only  calculates  the  steric  and  electrostatic  interactions,  
yet  CoMSIA  not  only  calculates  the  steric  and  electrostatic  interactions,  but  also  calculates  the 
hydrophobic, HB donor and HB acceptor interactions [30]. The basic assumption of CoMSIA is that a 
suitable  sampling  of  the  steric,  electrostatic,  hydrophobic  and  HB  acceptor  interactions  generated 
around  a  set  of  aligned  molecules  with  a  probe  atom  might  provide  all  important  features  for 
understanding their biological activities, and that the changes in binding affinities of ligands are related 
to changes in molecular properties [31]. Similar to CoMFA studies, the CoMSIA method employs a 
3D  lattice  with  regular  grid  points  separated  by  2Å  to  place  aligned  molecules.  CoMSIA  uses  a  
Gaussian-type  distance-dependent  function  to  assess  five  fields  of  different  physicochemical 
properties. The default value of 0.3 was used as attenuation factor [18,32]. Because of the different 
shape of the Gaussian function, CoMSIA similarity indices (AF) for a molecule j with atom i at a grid 
point q are calculated by Equation 1 as follows: 
 
2
,
q
,
iq r
ik k probe k F e j A
  
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where  ωprobe,k  is  the  probe  atom  with  radius  1Å,  charge  +1,  hydrophobicity  +1,  hydrogen  bond 
donating +1 and hydrogen bond accepting +1. ωik is the actual value of the physicochemical property k 
of atom i. riq is the mutual distance between the probe atom at grid point q and item i of the test 
molecule [33]. 
Furthermore, the  logP  value  of  a  compound,  which  is  the  logarithm  of  its  partition  coefficient 
between  n-octanol  and  water  log  (coctanol/cwater),  is  a  well  established  measure  of  the  compound’s 
hydrophilicity. In the present work, Clog P (calculated logP) was used as an additional descriptor in 
the CoMFA and CoMSIA analysis to study the effects of lipophilic parameters on activity.  
3.4. Partial Least Square Analysis 
Partial least-squares (PLS) methodology implemented in the QSAR model of SYBYL was used in 
deriving the 3D-QSAR models. This method replaces the original variables by a small set of linear 
combinations and is a variation of principal component regression [34,35]. In this work, PLS was used 
to analyze the training set by correlating the variation in their pIC50 values (the dependent variable) 
with  variations  in  their  CoMFA/CoMSIA  interaction  ﬁelds  (the  independent  variables).  Initially,  
cross-validation analysis was accomplished with the leave-one-out (LOO) methodology, where one 
compound was excluded from the original dataset and its activity was predicted by the new model 
derived from the rest of the database. That gives the LOO-CV (R
2) as a statistical index of predictive 
power. Then a non-cross-validation analysis was carried out to calculate the Pearson coefficient and 
the standard error of estimates (SEE). 
During PLS process, several statistical parameters including the Q
2 and the above R
2
ncv are crucial 
for evaluating the reliability of the model generated. As a cross-validated coefficient, Q
2 is used as a 
statistical index of the predictive power of the model, and is calculated by Equation 2 where the Ypredicted, 
Yobserved and Ymean are predicted, actual and mean values of the target property, respectively [36]. 
2
2
2
( )
1
( )
predicted observed
Y
observed mean
Y
Y Y
q
Y Y

 



  (2)  
In order to evaluate the real predictive ability of the best models generated by the CoMFA/CoMSIA 
analyses, 27 compounds are treated as the external validation set for activity I and 12 compounds for 
activity II. A predictive R value was then obtained with Equation 3: 
2 1 / pred r PRESS SD     (3)  
Where  SD  denotes  the  sum  of  squared  deviation  between  the  biological  activities  of  the  test  set 
molecule and the mean activity of the training set molecules, PRESS represents the sum of squared 
deviations between the experimental and predicted activities of the test molecules [37]. 
3.5. DISCOtech Analysis 
3D  pharmacophore  mappings  based  on  distance  comparison  technique  were  derived  from  the  
50  most  active  compounds  for  activity  I  and  activity  II  respectively.  Pharmacophore  models  in 
particular involve the identiﬁcation of the pharmacophoric pattern common to a set of known actives Int. J. Mol. Sci. 2011, 12                       
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and  the  use  of  this  pattern  in  a  subsequent  search.  DISCOtech™,  a  well  established  module  for 
designing pharmacophoric maps and frequently used in the process of virtual screening to discover 
new  leads,  is  employed  in  the  establishment  [38,39].  DISCOtech  identifies  features  that  could  be 
elements  in  a  pharmacophore  model  from  a  set  of  molecules  that  binds  to  a  common  binding  
site  [40,41].  These  features  include  hydrogen  bond  donor  atoms  (HD),  hydrogen  bond  acceptor  
atoms  (HA),  hydrogen  donor  (DS)  and  acceptor  site  (AA),  charge  centers,  centers  of  mass  of 
hydrophobic rings (HP), aromatic rings (AR) and positive N (PN). In this study, a stochastic search 
method  was  used  to  create  conformers  for  the  molecules.  The  maximum  number  of  conformers 
generated for each compound was 50, and seven conformers were then selected. The 50 most active 
molecules were employed with most active antagonist selected as reference compound. Min 4 and Max 
16 features were allowed to ﬁnd during the analysis. Tanimoto threshold was set as 0.6. All other 
parameters were retained as default values. The best DISCOtech pharmacophore model with relatively 
high score, more useful features and moderate pairwise tolerance was proposed.  
4. Conclusions  
In  this  paper,  the  3D-QSAR  studies  and  ligand-based  modeling  of  137  1,3-dihydro-
benzo[b][1,4]diazepin-2-one  derivatives  were,  for  the  ﬁrst  time,  performed  using  CoMFA  and 
CoMSIA tools. In 2008, a Chinese paper reported a model concerning affinity test using 30 compounds 
in the first one among the series of article [42]. Two series of models were built using statistics from 
affinity assay (activity I) and cell test (activity II) respectively. The constructed 3D-QSAR models 
exhibited proper predictive powers in both the internal and external tests. The resulting contour maps 
produced  by  the  models  provide  a  platform  for  the  screening  of  novel  inhibitors  and  enables  the 
interpretation  of  their  binding  models  to  mGluR2.  A  good  consistency  between  the  CoMFA  and 
CoMSIA  contour  maps  and  the  pharmacophore  model  was  observed,  proving  the  reliability  and 
robustness of the models. Overall, our main ﬁndings are summarized as follows: (1) Bulky substituents 
in R7, R3 and position A benefit activity I of the series of derivatives, and decrease the potency when 
projected in R8 and position B of ring D; (2) Hydrophilic groups at position A and B of Ring D may 
increase  the  antagonistic  activity  I;  (3)  Electrostatic  field  plays  an  essential  role  in  improving  the 
antagonism  of  the  compounds  performed  in  cAMP  assay  (activity  II);  (4)  An  H-donor  atom,  an  
H-donor acceptor atom, an H-donor site, two hydrophobic centers and an aromatic ring are shared 
pharmacophoric  features  of  the  two  models.  Besides,  for  pharmacophore  model  of  activity  II,  a 
positive N, an H-bond acceptor site and an additional aromatic ring are featured as essential characters 
of  potent  drugs. In  addition,  the  amino  acid  sequence  of the  human  mGluR2  receptor  consists  of  
872  residues  and  shows  a  sequence  identity  of  97%  to  the  amino  acid  sequence  of  rat  mGluR2,  
besides  highly  similar  anatomy,  thus  made  the  model  highly  applicable  to  create  human  mGluR2 
antagonists [43]. All the correlation of the results obtained from above QSAR and pharmacophore 
studies,  we  hope,  may  lead  to  a  better  understanding  of  the  structural  requirements  for  enhanced 
activity and help in the design of new and more potent mGluR2 antagonists. Int. J. Mol. Sci. 2011, 12                       
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